cinacalcet Articles
FDA suspends pediatric trial of Amgen's Sensipar after patient death
27 February 2013
Amgen 4th-qtr net profit plunges 16% but sales up; gets boost from fiscal cliff legislation
24 January 2013
AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld
10 January 2011
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
Falling profit on low sales for Amgen
27 April 2009
Amgen's 3rd-qtr 2008 profit leaps to $1.16B
3 November 2008
Amgen earnings down but outlook still up
4 August 2008
Barr confirms Sensipar patent challenge
4 August 2008
Amgen's Mimpara approved by EC
30 June 2008
Amgen reports nearly flat 1st qtr
5 May 2008
More NCEs added to Japan's NHI reimbursement list late December
14 January 2008
Japan OKs cinacalcet for CKD patients
5 November 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
NICE recommends Mimpara with caveats
29 January 2007
UK regulator gives nod to Amgen's Mimpara
13 November 2006
Amgen sees $1B profits in 1st-qtr 2006
24 April 2006
New product launches in 2004
31 January 2005
NPS completes $175M offering backed by Sensipar royalties
10 January 2005
Amgen's Mimpara cleared in EU
8 November 2004
Amgen's Mimpara gets OK from CHMP
9 August 2004
Amgen's Sensipar OKed by FDA
15 March 2004
Amgen submits cinacalcet in USA
15 September 2003
Amgen set to file for cinacalcet in 2003
28 April 2003
Showing 1-32 of 32 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
